Literature DB >> 24338689

A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.

Nahla E El-Ashmawy1, Rania M Khalil.   

Abstract

L-carnitine is an antioxidant and is found to be a protective agent against many diseases including cancer. This review illustrates the possible role of L-carnitine as an add-on therapy to breast cancer patients maintained on tamoxifen. The objectives of carnitine treatment are diverse: improving tamoxifen-related side effects, offering better cancer prognosis by reducing the risk of developing cancer recurrence or metastasis, and modulating the growth factors which may be, in part, a prospective illustration to overcome tamoxifen resistance. So, it could be recommended to supplement L-carnitine to breast cancer patients starting tamoxifen treatment.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24338689     DOI： 10.1007/s13277-013-1477-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  103 in total

Review 1.  Obesity-related sleepiness and fatigue: the role of the stress system and cytokines.

Authors:  Alexandros N Vgontzas; Edward O Bixler; George P Chrousos
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

2.  A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance.

Authors:  Julia S Samaddar; Virgil T Gaddy; Jennifer Duplantier; Sudharsan Periyasamy Thandavan; Manish Shah; Marlena J Smith; Darren Browning; Jim Rawson; Sylvia B Smith; John T Barrett; Patricia V Schoenlein
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson's disease.

Authors:  F M Puca; S Genco; L M Specchio; B Brancasi; R D'Ursi; A Prudenzano; A Miccoli; R Scarcia; R Martino; M Savarese
Journal:  Int J Clin Pharmacol Res       Date:  1990

Review 4.  L-carnitine in dialysis patients.

Authors:  S Ahmad
Journal:  Semin Dial       Date:  2001 May-Jun       Impact factor: 3.455

5.  Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.

Authors:  Stuart A Montgomery; L J Thal; R Amrein
Journal:  Int Clin Psychopharmacol       Date:  2003-03       Impact factor: 1.659

6.  Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.

Authors:  N I Ntukidem; A T Nguyen; V Stearns; M Rehman; A Schott; T Skaar; Y Jin; P Blanche; L Li; S Lemler; J Hayden; R M Krauss; Z Desta; D A Flockhart; D F Hayes
Journal:  Clin Pharmacol Ther       Date:  2007-08-22       Impact factor: 6.875

7.  L-carnitine supplementation in childhood epilepsy: current perspectives.

Authors:  D C De Vivo; T P Bohan; D L Coulter; F E Dreifuss; R S Greenwood; D R Nordli; W D Shields; C E Stafstrom; I Tein
Journal:  Epilepsia       Date:  1998-11       Impact factor: 5.864

8.  ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.

Authors:  Craig I Campbell; James J Petrik; Roger A Moorehead
Journal:  Mol Cancer       Date:  2010-09-08       Impact factor: 27.401

9.  L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death.

Authors:  G Sener; E Ekşioğlu-Demiralp; M Cetiner; F Ercan; S Sirvanci; N Gedik; B C Yeğen
Journal:  Cell Biol Toxicol       Date:  2006-01       Impact factor: 6.691

10.  Differentially expressed genes in Hirudo medicinalis ganglia after acetyl-L-carnitine treatment.

Authors:  Giuseppe Federighi; Monica Macchi; Rodolfo Bernardi; Rossana Scuri; Marcello Brunelli; Mauro Durante; Giovanna Traina
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240
View more
  6 in total

1.  Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice.

Authors:  Fang-Fang Gao; Jia-Wei Lv; Ying Wang; Rong Fan; Qun Li; Zun Zhang; Lei Wei
Journal:  Biomed Rep       Date:  2015-10-30

2.  Effect of hesperidin on mice bearing Ehrlich solid carcinoma maintained on doxorubicin.

Authors:  Naglaa F Khedr; Rania M Khalil
Journal:  Tumour Biol       Date:  2015-06-23

Review 3.  G-protein-coupled estrogen receptor as a new therapeutic target for treating coronary artery disease.

Authors:  Guichun Han; Richard E White
Journal:  World J Cardiol       Date:  2014-06-26

4.  Alter between gut bacteria and blood metabolites and the anti-tumor effects of Faecalibacterium prausnitzii in breast cancer.

Authors:  Ji Ma; Lingqi Sun; Ying Liu; Hui Ren; Yali Shen; Feng Bi; Tao Zhang; Xin Wang
Journal:  BMC Microbiol       Date:  2020-04-09       Impact factor: 3.605

5.  Identification of Tamoxifen-Resistant Breast Cancer Cell Lines and Drug Response Signature.

Authors:  Qingzhou Guan; Xuekun Song; Zhenzhen Zhang; Yizhi Zhang; Yating Chen; Jing Li
Journal:  Front Mol Biosci       Date:  2020-12-04

6.  Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.

Authors:  Caridad Díaz; Carmen González-Olmedo; Leticia Díaz-Beltrán; José Camacho; Patricia Mena García; Ariadna Martín-Blázquez; Mónica Fernández-Navarro; Ana Laura Ortega-Granados; Fernando Gálvez-Montosa; Juan Antonio Marchal; Francisca Vicente; José Pérez Del Palacio; Pedro Sánchez-Rovira
Journal:  Mol Oncol       Date:  2022-04-14       Impact factor: 7.449
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.